Oruka Therapeutics, Inc.
No enriched coverage for $ORKA in the last 7 days.
Goncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $86.28 ($84.36–$87.25, $0.60M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.
Agarwal Arjun (Senior Vice President, Finance) sold 9,999 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $84.63 ($83.07–$85.63, $0.85M total) across 4 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).
Recent ORKA coverage spans insider activity, financial news and mergers & acquisitions.
In the last 30 days, ORKA insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($1.5M). The most active reporter was Goncalves Joana, Chief Medical Officer, with 4 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is an insider sale disclosure, not an operational or financial update, so it is more of a sentiment/positioning signal than a fundamental catalyst.
This is an insider selling disclosure, not a fundamental update. It may slightly affect sentiment, but it does not change operating outlook based on the filing alone.
Phase 2a efficacy data provides a concrete catalyst for ORKA, supporting momentum trading and re-rating of probability-weighted outcomes.
Large conversion/sale can increase float and selling pressure, offset by the stock’s strong recent run.
Large insider/10% owner indirect open-market sale may modestly pressure sentiment, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions ORKA with an AI model for sentiment and relevance, and aggregates insider trades from Oruka Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Goncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $86.28 ($84.36–$87.25, $0.60M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.
2 min readAgarwal Arjun (Senior Vice President, Finance) sold 9,999 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $84.63 ($83.07–$85.63, $0.85M total) across 4 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
2 min readIn June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).
4 min readInvesting.com roundup of US insider trades: Jewett-Cameron (JCTC) 10% owners bought $806k (353,607 shares) June 29; RH director bought 11,388 shares for $1.83m; Faeth Therapeutics CFO bought 13,634 shares for $326k; GitLab CEO bought 4,188 shares for $123k. Sells: Oruka (ORKA) fund sold 3.55m shares for $300m; AMAT CEO sold 78,321 shares ~$55.5m; Airbnb director sold 294,903 shares ~$43.8m; Snowflake director sold 99,900 shares ~$25.1m; Workday owner sold 107,500 shares ~$13.1m.
6 min readFairmount Funds Management LLC sold 3,553,410 indirectly-held shares of Oruka Therapeutics, Inc. (ORKA) at $84.43 ($300.01M total) on 2026-07-01.
1 min readOruka Therapeutics (NASDAQ: ORKA) said its SVP of Finance Arjun Agarwal sold 9,854 shares of common stock for about $687,000, per an SEC Form 4 filed for June 12 and June 15, 2026. The sale followed option exercises and reduced his direct holdings from 26,753 to 16,899 shares (~36.8%). Oruka’s stock closed June 15, 2026 at $68.86.
6 min readHC Wainwright reissued a “buy” rating for Oruka Therapeutics (NASDAQ: ORKA) and set a $120.00 price target, implying 40.55% upside from the stock’s level at the time. Other analysts cited include UBS ($100), Guggenheim ($200), Piper Sandler ($180), and BTIG ($151). ORKA shares opened at $85.38; last reported EPS was -$0.48 vs -$0.52 expected.
5 min readOruka Therapeutics Inc. shares rose more than 14% to $82.77 in Monday morning trading, according to market reports. The article attributes the move to positive investor sentiment tied to progress in the company’s clinical pipeline and increased activity in healthcare biotech. It notes higher-than-usual volume and that biotech stocks often react to trial and regulatory updates.
3 min readAgarwal Arjun (Senior Vice President, Finance) sold 9,854 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $69.72 ($68.34–$70.34, $0.69M total) across 4 trades over 2026-06-12 to 2026-06-15 under a Rule 10b5-1 trading plan.
2 min readGoncalves Joana (Chief Medical Officer) sold 7,947 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $69.28 ($68.38–$70.62, $0.55M total) across 4 trades on 2026-06-15 under a Rule 10b5-1 trading plan.
1 min read
